Nipro Diagnostics Inc.’s acquisition by China-based Sinocare Group was headed to the finish line when it suddenly looked like the deal could be upended.
At 8 p.m. Eastern time on Jan. 7, four hours before the scheduled closing, “we caught word the Chinese stock exchange was experiencing a steep selloff and trading was halted,” said Greenberg Traurig corporate and securities shareholder Matthew Miller. “We were nervous for the next four or five hours.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
